Core Insights - The article discusses the confusion between atopic dermatitis (AD) and eczema, highlighting that AD is a specific type of eczema with distinct characteristics [1] - It emphasizes the prevalence of AD in China, with over 70 million patients, and the common misconceptions surrounding the disease [1] - The article outlines the importance of proper diagnosis and treatment methods for managing AD effectively [2][4] Group 1: Disease Understanding - Atopic dermatitis is characterized by chronic inflammation, severe itching, and recurrent episodes, with about 60% of patients also suffering from allergic rhinitis or asthma [1] - The disease has a significant familial aggregation, with a 50% chance of children developing AD if one parent is affected [1] - The "Zhang's criteria" for diagnosis requires meeting two out of three conditions: chronic or recurrent symmetrical eczema, personal or family history of allergies, and elevated serum IgE or eosinophils [1] Group 2: Treatment Approaches - The "three-dimensional anti-itch method" includes cold compresses, moisturizing creams, and medication, with innovative topical agents like Zeli Mei showing promising results [2] - Clinical data indicates that 61.5% of patients in an 8-week trial achieved complete clearance of skin lesions, with rapid itch relief observed within 2 hours [2] - The drug is priced significantly lower in China at 360 yuan compared to 1,400 USD in the U.S., easing the financial burden on patients [2] Group 3: Long-term Management - Active maintenance treatment is crucial, with recommendations for preventive use of Zeli Mei even after symptoms disappear, reducing the risk of recurrence by 60% [4] - Keeping a "itch diary" to track triggers such as temperature and diet is advised for better management of the condition [4] - The drug has been approved for use in children over 2 years old, showing over 80% clearance rate in clinical trials with minimal side effects [4]

Core Insights - The 2025 Academic Annual Meeting of the Chinese Association of Integrative Medicine for Dermatology and Venereology was held in Shanghai, focusing on advancements in dermatology and integrative therapies [1] - A new drug for atopic dermatitis (AD), Zeli Mei, was highlighted as a significant breakthrough in the field, showcasing a unique mechanism of action [1] Group 1: Drug Characteristics - Zeli Mei has five key characteristics: rapid onset of action, significant efficacy, outstanding therapeutic effects comparable to systemic treatments, durable effects with low relapse rates, and excellent safety profile [2] - Clinical data shows that Zeli Mei improves itching symptoms within the first day and significantly enhances skin lesions within seven days [2] - The EASI75 response rate after eight weeks of treatment is 54.4%, with even higher rates in children aged 2 to 17 years, reaching 69.2% and 83.9% in the 7 to 11 age group [2] Group 2: Expert Opinions - Experts at the conference responded positively to the presentation, noting the significant improvement in patients' itching and scratching behaviors after using Zeli Mei [3] - The drug offers a new option for clinicians, especially for children, due to its efficacy and safety, providing an alternative to traditional non-steroidal medications [3] - Zeli Mei, designed specifically for AD and based on the innovative AhR modulation mechanism, presents substantial therapeutic potential [3]